drugset / Trial / NCT01398293
A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
RandomizedCrossoverDouble-blind
Summary
This single-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled four-way crossover study will evaluate the effect of a single dose of danoprevir with low-dose ritonavir on the QC/QTc interval in healthy volunteers. Subjects will be randomly assigned to one of four sequences with treatments of A: therapeutic dose of danoprevir plus ritonavir (DNV/r), B: supratherapeutic dose of DNV/r, C: moxifloxacin and D: placebo, with a washout period of at least 7 days between treatments.
Timeline
- Start
- 2011-08
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |
| Subject | danoprevir | Small molecule | 100 mg | Oral |
| Subject | danoprevir | Small molecule | 400 mg | Oral |
Indications
No indication recorded.